Search Result

Results for "

neurotransmitters dopamine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dopamine Receptor (22) Dopamine Transporter (3) 5-HT Receptor (6) Adrenergic Receptor (1) Amyloid-β (1) Apoptosis (2) Autophagy (5) Biochemical Assay Reagents (1) Calcium Channel (3) Caspase (2) COX (2) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (12) Enterovirus (3) ERK (1) Ferroptosis (4) Fluorescent Dye (1) Histamine Receptor (3) Histone Methyltransferase (1) Interleukin Related (2) Isotope-Labeled Compounds (6) mAChR (1) Mitophagy (2) Monoamine Oxidase (1) Monoamine Transporter (4) Neuropeptide Y Receptor (1) Opioid Receptor (1) p38 MAPK (2) PGE synthase (2) Reactive Oxygen Species (1) Serotonin Transporter (2)
By Research Areas:	Cancer (5) Infection (3) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (36)

By Targets:

Dopamine Receptor (22)

Dopamine Transporter (3)

5-HT Receptor (6)

Adrenergic Receptor (1)

Amyloid-β (1)

Apoptosis (2)

Autophagy (5)

Biochemical Assay Reagents (1)

Calcium Channel (3)

Caspase (2)

COX (2)

Drug Derivative (1)

Drug Metabolite (2)

Endogenous Metabolite (12)

Enterovirus (3)

ERK (1)

Ferroptosis (4)

Fluorescent Dye (1)

Histamine Receptor (3)

Histone Methyltransferase (1)

Interleukin Related (2)

Isotope-Labeled Compounds (6)

mAChR (1)

Mitophagy (2)

Monoamine Oxidase (1)

Monoamine Transporter (4)

Neuropeptide Y Receptor (1)

Opioid Receptor (1)

p38 MAPK (2)

PGE synthase (2)

Reactive Oxygen Species (1)

Serotonin Transporter (2)

By Research Areas:

Cancer (5)

Infection (3)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (36)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Dopamine Receptor Dopamine Transporter Dopamine β-hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0451

Dopamine 5+ Cited Publications ASL279 free base	Dopamine Receptor Endogenous Metabolite Ferroptosis	Neurological Disease
Dopamine is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine plays several important roles in the brain and body . Dopamine acts through *D2 dopamine* receptor**s to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-B0451A

Dopamine hydrochloride 5+ Cited Publications ASL279	Dopamine Receptor Endogenous Metabolite Ferroptosis	Neurological Disease
Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through *D2 dopamine* receptor**s to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0304

L-DOPA 20+ Cited Publications Levodopa; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-124767

SR 142948A	Neuropeptide Y Receptor	Neurological Disease
SR 142948A is a non-peptide neuropeptide neuropeptin (NT) receptor antagonist. SR 142948A is able to bind to neuropeptin receptors, especially with high affinity for NT1 and NT2 receptors. SR 142948A is mainly used to study the role of neuropeptide in the neurotransmitter system, especially the dopamine system .

HY-W011963

Melevodopa hydrochloride	Dopamine Receptor	Neurological Disease
Melevodopa hydrochloride is an effervescent Levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease

HY-B0451AR

Dopamine (hydrochloride) (Standard)	Dopamine Receptor Endogenous Metabolite Ferroptosis	Neurological Disease
Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-122278

Melevodopa	Dopamine Receptor	Neurological Disease
Melevodopa is an effervescent levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease .

HY-16731

Sembragiline EVT 302; RG1577; RO4602522	Monoamine Oxidase Reactive Oxygen Species	Neurological Disease
Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity .

HY-110019

Indatraline hydrochloride Lu 19-005	Serotonin Transporter Dopamine Transporter	Neurological Disease
Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis .

HY-14472

Tesofensine NS-2330	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .

HY-103465B

FFN511 hydrochloride	Monoamine Transporter	Others
FFN511 (hydrochloride) is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 (hydrochloride) inhibits serotonin binding to VMA T2-containing membranes with an IC₅₀ of 1 µM. FFN511 (hydrochloride) directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .

HY-103465

FFN511	Monoamine Transporter	Others
FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC₅₀ of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .

HY-101540

NMI 8739	Dopamine Receptor	Neurological Disease
NMI 8739 is a dopamine D₂ autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

HY-121650

ADTN	Dopamine Receptor	Neurological Disease
ADTN is a dopamine receptor agonist that has the activity of promoting dopamine neurotransmission. ADTN can be used to increase the release of neurotransmitters, thereby improving dopamine-related physiological functions. ADTN's potential applications include inhibiting mental illness and improving cognitive function .

HY-B0451AS7

Dopamine-d5 hydrochloride	Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite Ferroptosis	Neurological Disease
Dopamine-d₅ (hydrochloride) is the deuterium labeled Dopamine (hydrochloride). Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body[1]. Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis[1].

HY-W778608R

Quercetin 7-glucuronide (Standard)	Drug Metabolite	Inflammation/Immunology
Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-Y0123S2

DL-Tyrosine-d2	Isotope-Labeled Compounds	Neurological Disease
DL-Tyrosine-d₂ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123S3

DL-Tyrosine-d3	Isotope-Labeled Compounds	Neurological Disease
DL-Tyrosine-d₃ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123S1

DL-Tyrosine-d7	Isotope-Labeled Compounds	Neurological Disease
DL-Tyrosine-d₇ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123

DL-Tyrosine	Drug Derivative	Neurological Disease
DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .

HY-129097

FFN-102 trifluoroacetate	Fluorescent Dye	Others
FFN-102 trifluoroacetate is an analogue of biogenic neurotransmitters. FFN-102 trifluoroacetate is a pH-dependent fluorescent probe that labels dopamine cell bodies, axons, and presynaptic terminals .

HY-Y0123S

DL-Tyrosine-13C9,15N	Isotope-Labeled Compounds	Neurological Disease
DL-Tyrosine- ¹³C₉, ¹⁵N is the ¹³C- and ¹⁵N-labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1].

HY-132392S

L-DOPA-2,5,6-d3	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S

L-DOPA-d6 Levodopa-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304S2

L-DOPA-13C 1 Publications Verification	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-N0304S1

L-DOPA-13C6 Levodopa-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-W250174

Lithium 3,5-diiodosalicylate 3,5-Diiodosalicylic acid lithium salt	Biochemical Assay Reagents	Others
Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.

HY-137546

Reduced Haloperidol Haloperidol metabolite II	Drug Metabolite
Reduced Haloperidol (Haloperidol metabolite II) is an antipsychotic compound with neurotransmitter modulating activity. Reduced Haloperidol is commonly used to inhibit schizophrenia and other psychotic disorders. Reduced Haloperidol helps reduce the occurrence of hallucinations and delusions by inhibiting the activity of dopamine receptors.

HY-118406A

Ethybenztropine hydrochloride Ponalid hydrochloride; UK 738 hydrochloride	mAChR	Neurological Disease
Ethybenztropine hydrochloride (Ponalid hydrochloride) is an anticholinergic drug with antiparkinsonian activity. Ethybenztropine hydrochloride may also have dopamine reuptake inhibitory effects. Ethybenztropine hydrochloride is used to improve motor symptoms in patients with Parkinson's disease. Ethybenztropine hydrochloride exerts its inhibitory effects by regulating the balance of neurotransmitters .

HY-137332

N-Methylspiroperidol	Dopamine Receptor	Neurological Disease
N-Methylspiroperidol is a D2 receptor antagonist. N-Methylspiroperidol can be labeled as [18F]N-Methylspiroperidol and used in PET (Positron Emission Tomography) to study how it binds to the 5-HT2C receptor and the competition and effects of neurotransmitters like dopamine on these receptors .

HY-141468

β-Chlornaltrexamine dihydrochloride β-CNA dihydrochloride	Opioid Receptor	Neurological Disease
β-Chlornaltrexamine dihydrochloride (β-CNA dihydrochloride) is a potent long-term opioid receptor blocker. β-Chlornaltrexamine dihydrochloride can effectively block the inhibitory effect of κ opioid receptor agonists on dopamine release. β-Chlornaltrexamine dihydrochloride can be used to study the mechanism of pain perception .

HY-116062

JNJ-7925476 hydrochloride	Monoamine Transporter Dopamine Transporter Adrenergic Receptor	Others
JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.

HY-133858

25N-NBOMe hydrochloride	5-HT Receptor	Neurological Disease
25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with K_i values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters .

HY-W417914

4-Methylamphetamine hydrochloride 4-MA hydrochloride	5-HT Receptor Monoamine Transporter Dopamine Receptor	Neurological Disease
4-Methylamphetamine hydrochloride is a 5-HT1A receptor agonist that induces hypothermia in rats by binding to the 5-HT1A receptor. Additionally, 4-Methylamphetamine hydrochloride acts on norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters to increase the extracellular levels of these neurotransmitters. 4-Methylamphetamine hydrochloride can be used in the study of neurological disorders .

HY-W011727A

Pyridoxal 5'-phosphate monohydrate 1 Publications Verification Pyridoxal phosphate monohydrate	Endogenous Metabolite Amyloid-β ERK	Neurological Disease Metabolic Disease Cancer
Pyridoxal 5'-phosphate hydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate hydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′‐phosphate (PMP) .

HY-B1081

Oxidopamine hydrochloride Maximum Cited Publications 24 Publications Verification 6-Hydroxydopamine Hydrochloride	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the **neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β** secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-B1081A

Oxidopamine hydrobromide Maximum Cited Publications 24 Publications Verification 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the **neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β** secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-117542

D595	Histone Methyltransferase	Neurological Disease
D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers .

HY-A0095S1

Flibanserin-d4-1 BIMT-17-d₄-1; BIMT-17BS-d₄-1	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Flibanserin-d₄-1 is deuterium labeled Flibanserin. Flibanserin (BIMT-17) is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM). Flibanserin binds to dopamine D4 receptors (4-24 nM), and has negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin is efficacious in treating hypoactive sexual desire disorder (HSDD)[1][2].

HY-B1693

Levomepromazine 1 Publications Verification Methotrimeprazine	5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel	Infection Neurological Disease Inflammation/Immunology
Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca ²⁺ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca ²⁺ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including *dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy*. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .

HY-W344044

Levomepromazine maleate Methotrimeprazine maleate	5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel	Infection Neurological Disease Inflammation/Immunology
Levomepromazine maleate (Methotrimeprazine maleate) is an orally active antipsychotic compound and Ca ²⁺ release inducer. Levomepromazine maleate inhibits SERCA pump and induces an increase in cytoplasmic Ca ²⁺ levels. Levomepromazine maleate has antagonistic effects on a variety of neurotransmitter receptors, including *dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine maleate can induce adaptive ER stress and autophagy*. In addition, Levomepromazine maleate has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine maleate can be used in the study psychiatric disorders and relieving nausea and vomiting .

HY-B1693R

Levomepromazine (Standard) Methotrimeprazine (Standard)	5-HT Receptor Dopamine Receptor Autophagy Histamine Receptor Enterovirus Calcium Channel	Infection Neurological Disease Inflammation/Immunology
Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca ²⁺ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca ²⁺ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including *dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy*. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .

Cat. No.	Product Name

HY-L062

Neurotransmitter Receptor Compound Library	2,112 compounds
Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding. In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy. MCE designs a unique collection of 2,112 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

Neurotransmitter Receptor Compound Library

2,112 compounds

Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding.

In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy.

MCE designs a unique collection of 2,112 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

HY-L165

Dopamine Receptor Compound Library

222 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 222 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.	Product Name	Type

HY-W250174

Lithium 3,5-diiodosalicylate 3,5-Diiodosalicylic acid lithium salt	Biochemical Assay Reagents
Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0451

Dopamine 5+ Cited Publications ASL279 free base	Structural Classification Phenols Polyphenols Endogenous metabolite	Dopamine Receptor Endogenous Metabolite Ferroptosis
Dopamine is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine plays several important roles in the brain and body . Dopamine acts through *D2 dopamine* receptor**s to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-B0451A

Dopamine hydrochloride 5+ Cited Publications ASL279	Structural Classification Microorganisms Source classification Phenols Polyphenols Endogenous metabolite	Dopamine Receptor Endogenous Metabolite Ferroptosis
Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through *D2 dopamine* receptor**s to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0304

L-DOPA Maximum Cited Publications 21 Publications Verification Levodopa; 3,4-Dihydroxyphenylalanine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-Y0123

DL-Tyrosine	Structural Classification Monophenols Source classification Phenols Amino acids Endogenous metabolite	Drug Derivative
DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-W011727A

Pyridoxal 5'-phosphate monohydrate 1 Publications Verification Pyridoxal phosphate monohydrate	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Amyloid-β ERK
Pyridoxal 5'-phosphate hydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate hydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′‐phosphate (PMP) .

HY-B0451AR

Dopamine (hydrochloride) (Standard)	Structural Classification Microorganisms Source classification Phenols Polyphenols Endogenous metabolite	Dopamine Receptor Endogenous Metabolite Ferroptosis
Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-W778608R

Quercetin 7-glucuronide (Standard)	Structural Classification Flavonols Flavonoids Source classification Pedaliaceae Plants Uncarina grandidieri (Baill.) Ihlenf. & Straka	Drug Metabolite
Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

Cat. No.	Product Name	Chemical Structure

HY-B0451AS7

Dopamine-d5 hydrochloride

Dopamine-d₅ (hydrochloride) is the deuterium labeled Dopamine (hydrochloride). Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body[1]. Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis[1].

HY-Y0123S

DL-Tyrosine-13C9,15N
DL-Tyrosine- ¹³C₉, ¹⁵N is the ¹³C- and ¹⁵N-labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1].

HY-132392S

L-DOPA-2,5,6-d3
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S

L-DOPA-d6
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304S2

L-DOPA-13C 1 Publications Verification
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-A0095S1

Flibanserin-d4-1

Flibanserin-d₄-1 is deuterium labeled Flibanserin. Flibanserin (BIMT-17) is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM). Flibanserin binds to dopamine D4 receptors (4-24 nM), and has negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin is efficacious in treating hypoactive sexual desire disorder (HSDD)[1][2].

HY-Y0123S2

DL-Tyrosine-d2
DL-Tyrosine-d₂ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123S3

DL-Tyrosine-d3
DL-Tyrosine-d₃ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123S1

DL-Tyrosine-d7
DL-Tyrosine-d₇ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-N0304S1

L-DOPA-13C6
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

neurotransmitters dopamine

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products